Imaging outcomes | Groups n(%)/n(%) | OR for PsA diagnosis (95% CI) | P value* | Risk ratio for PsA (95% CI) | |
MRI DIP-joint synovial hypertrophy | PsA/PsO | 75 (45)/14 (39) | 1.27 (0.61 to 2.65) | 0.528 | 1.15 (0.74 to 1.79) |
PsA/OA | 75 (45)/42 (88) | 0.12 (0.05 to 0.29) | <0.001 | 0.51 (0.42 to 0.62) | |
MRI Tenosynovitis | PsA/PsO | 58 (35)/18 (50) | 0.53 (0.26 to 1.09) | 0.081 | 0.69 (0.47 to 1.02) |
PsA/OA | 558 (35)/35 (73) | 0.20 (0.10 to 0.40) | <0.001 | 0.47 (0.36 to 0.62) | |
MRI New bone formation | PsA/PsO | 101 (60)/27 (61) | 0.95 (0.48 to 1.88) | 0.881 | 0.98 (0.75 to 1.28) |
PsA/OA | 101 (60)/45 (94) | 0.10 (0.03 to 0.34) | <0.001 | 0.64 (0.56 to 0.74) | |
MRI Periarticular inflammation | PsA/PsO | 82 (49)/24 (60) | 0.64 (0.32 to 1.28) | 0.205 | 0.81 (0.61 to 1.09) |
PsA/OA | 82 (49)/43 (90) | 0.11 (0.04 to 0.29) | <0.001 | 0.55 (0.45 to 0.65) | |
MRI Bone marrow oedema | PsA/PsO | 24 (14)/7 (16) | 0.88 (0.35 to 2.20) | 0.786 | 0.90 (0.41 to 1.95) |
PsA/OA | 24 (14)/34 (71) | 0.07 (0.03 to 0.15) | <0.001 | 0.20 (0.13 to 0.31) | |
MRI Erosions | PsA/PsO | 25 (15)/3 (7) | 2.41 (0.69 to 8.37) | 0.168 | 2.20 (0.70 to 6.94) |
PsA/OA | 25 (15)/31 (65) | 0.10 (0.05 to 0.20) | <0.001 | 0.23 (0.15 to 0.35) | |
X-ray Erosions | PsA/PsO | 156 (80)/37 (77) | 1.16 (0.54 to 2.47) | 0.702 | 1.03 (0.87 to 1.22) |
PsA/OA | 156 (80)/52 (100) | n.e. | ā | 0.80 (0.74 to 0.85) | |
X-ray Entheseal change | PsA/PsO | 167 (85)/38 (80) | 1.52 (0.68 to 3.37) | 0.309 | 1.08 (0.92 to 1.26) |
PsA/OA | 167 (85)/52 (100) | n.e. | ā | 0.85 (0.80 to 0.90) | |
US DIP-joint synovial hypertrophy | PsA/PsO | 86 (43)/12 (27) | 2.01 (0.98 to 4.13) | 0.057 | 1.58 (0.95 to 2.62) |
PsA/OA | 86 (43)/34 (65) | 0.40 (0.21 to 0.76) | 0.005 | 0.66 (0.51 to 0.85) | |
US Doppler signals | PsA/PsO | 4 (2)/1 (2) | 0.88 (0.10 to 8.05) | 0.908 | 0.88 (0.10 to 7.68) |
PsA/OA | 4 (2)/5 (10) | 0.20 (0.10 to 0.74) | 0.017 | 0.21 (0.06 to 0.75) | |
US Erosions | PsA/PsO | 24 (12)/1 (2) | 5.86 (0.77 to 44.56) | 0.087 | 5.28 (0.73 to 38.00) |
PsA/OA | 24 (12)/5 (10) | 1.28 (0.46 to 3.54) | 0.632 | 1.25 (0.50 to 3.11) | |
US New bone formation | PsA/PsO | 90 (45)/13 (30) | 1.95 (0.96 to 3.95) | 0.063 | 1.52 (0.25 to 2.47) |
PsA/OA | 90 (45)/45 (87) | 0.13 (0.06 to 0.30) | <0.001 | 0.52 (0.43 to 0.63) | |
US Extensor tendon enthesitis | PsA/PsO | 85 (43)/17 (39) | 1.17 (0.60 to 2.29) | 0.638 | 1.10 (0.73 to 1.65) |
PsA/OA | 85 (43)/15 (29) | 1.82 (0.94 to 3.54) | 0.075 | 1.48 (0.93 to 2.33) | |
US Peritendonitis | PsA/PsO | 26 (13)/2 (5) | 3.14 (0.72 to 13.75) | 0.111 | 2.86 (0.71 to 11.61) |
PsA/OA | 26 (13)/4 (8) | 1.79 (0.60 to 5.39) | 0.298 | 1.69 (0.62 to 4.63) |
*P value for OR calculated by Mantel-Haenszel Common OR Estimate. Bold values are statistical significant pā¤0.05.
DIP, distal interphalangeal; n.e., not estimable; OA, osteoarthritis; PsA, psoriatic arthritis; PsO, skin psoriasis; US, ultrasound.